XNYS
HLN
Market cap44bUSD
Apr 04, Last price
9.89USD
1D
-5.36%
1Q
4.55%
IPO
33.47%
Name
HALEON PLC
Chart & Performance
P/E
66.09
P/S
6.13
EPS
0.12
Div Yield, %
1.60%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
11.30b
+4.09%
Net income
1.05b
-1.04%
CFO
2.10b
+1.79%
Dividend
Aug 16, 20240.051416 USD/sh
Earnings
May 08, 2025
Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 11,302,000 4.09% | 10,858,000 13.76% | |||
Cost of revenue | 8,940,000 | 9,064,000 | |||
Unusual Expense (Income) | |||||
NOPBT | 2,362,000 | 1,794,000 | |||
NOPBT Margin | 20.90% | 16.52% | |||
Operating Taxes | 517,000 | 499,000 | |||
Tax Rate | 21.89% | 27.81% | |||
NOPAT | 1,845,000 | 1,295,000 | |||
Net income | 1,049,000 -1.04% | 1,060,000 -23.74% | |||
Dividends | (388,000) | (2,682,000) | |||
Dividend yield | |||||
Proceeds from repurchase of equity | (38,000) | ||||
BB yield | |||||
| Debt | |||||
Debt current | 656,000 | 437,000 | |||
Long-term debt | 8,937,000 | 10,164,000 | |||
Deferred revenue | |||||
Other long-term liabilities | 3,886,000 | 384,000 | |||
Net debt | 8,484,000 | 9,917,000 | |||
| Cash flow | |||||
Cash from operating activities | 2,100,000 | 2,063,000 | |||
CAPEX | (234,000) | (328,000) | |||
Cash from investing activities | (134,000) | (8,784,000) | |||
Cash from financing activities | (1,568,000) | 6,911,000 | |||
FCF | 1,764,000 | 2,561,000 | |||
| Balance | |||||
Cash | 1,044,000 | 684,000 | |||
Long term investments | 65,000 | ||||
Excess cash | 543,900 | 141,100 | |||
Stockholders' equity | 27,689,000 | 26,948,000 | |||
Invested Capital | 29,527,100 | 26,929,900 | |||
ROIC | 6.54% | 4.76% | |||
ROCE | 7.85% | 5.85% | |||
| EV | |||||
Common stock shares outstanding | 9,263,000 | 4,619,500 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | 2,671,000 | 2,081,000 | |||
EV/EBITDA | |||||
Interest | 414,000 | 258,000 | |||
Interest/NOPBT | 17.53% | 14.38% | |||